Patients with coronary artery disease or heart failure have been shown to be insulin resistant. Whether in these patients heart muscle participates in the insulin resistance, and whether reduced blood flow is a mechanism for such resistance is not known. We measured heart and skeletal muscle blood flow and glucose uptake during euglycemic hyperinsulinemia (insulin clamp) in 15 male patients with angiographically proven coronary artery disease and chronic regional wall motion abnormalities. Six age- and weight-matched healthy subjects served as controls. Regional glucose uptake was measured by positron emission tomography using [18F]2-fluoro-2-deoxy-D-glucose (FDG), blood flow was measured by the H2(15)O method. Myocardial glucose utilization was measured in regions with normal perfusion and wall motion as assessed by radionuclide ventriculography. Whole-body glucose uptake was 37+/-4 micromol x min(-1) x kg(-1) in controls and 14+/-2 mciromol x min(-1) x kg(-1) in patients (P = 0.001). Myocardial blood flow (1.09+/-0.06 vs. 0.97+/-0.04 ml x min(-1) x g(-1), controls vs. patients) and skeletal muscle (arm) blood flow (0.046+/-0.012 vs. 0.043+/-0.006 ml x min(-1) x g(-1)) were similar in the two groups (P = NS for both). In contrast, in patients both myocardial (0.38+/-0.03 vs. 0.70+/-0.03 micromol x min(-1) x g(-1), P = 0.0005) and muscle glucose uptake (0.026+/-0.004 vs. 0.056+/-0.006 micromol x min(-1) x g(-1), P = 0.005) were markedly reduced in comparison with controls. In the whole dataset, a direct relationship existed between insulin-stimulated glucose uptake in heart and skeletal muscle. Patients with a history of myocardial infarction and a low ejection fraction are insulin resistant. This insulin resistance affects both the myocardium and skeletal muscle and is independent of blood flow.
G Paternostro, P G Camici, A A Lammerstma, N Marinho, R R Baliga, J S Kooner, G K Radda, E Ferrannini
Title and authors | Publication | Year |
---|---|---|
Pharmacotherapy of Cachexia
W Doehner |
Pharmacotherapy of Cachexia | 2005 |
Measurement of skeletal muscle glucose utilization by dynamic 18F-FDG PET without arterial blood sampling
I Yokoyama, Y Inoue, T Moritan, K Ohtomo, R Nagai |
Nuclear Medicine Communications | 2005 |
Clinical indicators of biochemical remission in acromegaly: does incomplete disease control always mean therapeutic failure?
SS Damjanovic, AN Neskovic, MS Petakov, V Popovic, D Macut, P Vukojevic, MM Joksimovic |
Clinical Endocrinology | 2005 |
Therapy Insight: heart disease and the insulin-resistant patient
SA Cook, T Aitman, RP Naoumova |
Nature Clinical Practice Cardiovascular Medicine | 2005 |
Rosiglitazone Treatment in Zucker Diabetic Fatty Rats Is Associated With Ameliorated Cardiac Insulin Resistance and Protection From Ischemia/Reperfusion-Induced Myocardial Injury
TL Yue, W Bao, JL Gu, J Cui, L Tao, XL Ma, EH Ohlstein, BM Jucker |
Diabetes | 2005 |
Rosiglitazone improves myocardial glucose uptake in patients with type 2 diabetes and coronary artery disease: a 16-week randomized, double-blind, placebo-controlled study
Riikka Lautamäki, K E Juhani Airaksinen, Marko Seppänen, Jyri Toikka, Matti Luotolahti, Elizabeth Ball, Ronald Borra, Risto Härkönen, Patricia Iozzo, Murray Stewart, Juhani Knuuti, Pirjo Nuutila |
Diabetes | 2005 |
Influence of insulin and free fatty acids on contractile function in patients with chronically stunned and hibernating myocardium
H Wiggers, H Nørrelund, SS Nielsen, NH Andersen, JE Nielsen-Kudsk, JS Christiansen, TT Nielsen, N Møller, HE Bøtker |
American journal of physiology. Heart and circulatory physiology | 2005 |
Endothelial Function and Coronary Spastic Angina
H KAWANO, H OGAWA |
Internal Medicine | 2005 |